Journal article
Management of Resistant Trichomoniasis
Current infectious disease reports, v 21(9)
06 Aug 2019
PMID: 31388764
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Purpose of Review Trichomonas vaginalis is the most prevalent sexually transmitted parasite in the USA; resistant infection is emerging. New drug therapies and dosing regimens of standard therapies are being studied to treat resistant infection. Recent Findings Diagnosis of trichomoniasis has become more sensitive, specific, and widely available with the advent of nucleic acid amplification tests (NAATs). Women with resistant trichomoniasis should be treated with high-dose regimens of metronidazole or tinidazole. Alternative treatment options have been described, and there has been some success particularly with high-dose tinidazole/intravaginal paromomycin cream combination, intravaginal boric acid, and intravaginal metronidazole/miconazole. Resistant trichomoniasis is a growing public health concern with implications for long-term health consequences. More data are needed to further evaluate mechanisms by which resistance occurs as well as promising therapies for those affected.
Metrics
Details
- Title
- Management of Resistant Trichomoniasis
- Creators
- Cynthia Alessio - Drexel UniversityPaul Nyirjesy - Drexel University
- Publication Details
- Current infectious disease reports, v 21(9)
- Publisher
- Springer Nature
- Number of pages
- 7
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000479038100001
- Scopus ID
- 2-s2.0-85070208712
- Other Identifier
- 991019350581204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Infectious Diseases